menu
    • menu
    [{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"OMERS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Glecaprevir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Enanta Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20000000000000001,"dosageForm":"Tablet","sponsorNew":"Enanta Pharmaceuticals \/ OMERS Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Enanta Pharmaceuticals \/ OMERS Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals for Glecaprevir

    Menu

    Glecaprevir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecaprevir,Pibrentasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : OMERS Life Sciences

                            Deal Size : $200.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.)...

                            Details : Through the divestment, Enanta will sale a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) to OMERS Life Sciences. The net sale proceeds will be used to fund the continuing clinical development of virology p...

                            Brand Name : Mavyret

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 25, 2023

                            Lead Product(s) : Glecaprevir,Pibrentasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : OMERS Life Sciences

                            Deal Size : $200.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth